Imunon Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
IMNN$0.88+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | |||
|---|---|---|---|
| 2023 · 2022 | |||
| Licensing revenue | $ | - | $500,000 |
| Operating expenses: | |||
| Research and development | 11,287,691 | 11,733,666 | |
| General and administrative | 9,742,739 | 13,687,899 | |
| Total operating expenses | 21,030,430 | 25,421,565 | |
| Loss from operations | (21,030,430) | (24,921,565) | |
| Other income (expense): | |||
| Gain from change in earn-out milestone liability | - | 5,396,000 | |
| Impairment of in-process research and development | - | (13,366,234) | |
| Loss on debt extinguishment | (329,158) | - | |
| Investment income, net | 1,157,625 | 453,356 | |
| Interest expense | (197,080) | (5,028,618) | |
| Other (loss) income | (396,319) | 1,801 | |
| Total other income (expense), net | 235,068 | (12,543,695) | |
| Loss before income tax benefit | (20,795,362) | (37,465,260) | |
| Income tax benefit | 1,280,385 | 1,567,026 | |
| Net loss | $(19,514,977) | $(35,898,234) | |
| Net loss per common share - basic and diluted | $(2.16) | $(5.03) | |
| Weighted average common shares outstanding - basic and diluted | 9,045,320 | 7,142,970 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.